Skip to main content
Hangzhou Jiuyuan Gene Engineering Co., Ltd. logo

Hangzhou Jiuyuan Gene Engineering Co., Ltd. — Investor Relations & Filings

Ticker · 2566 ISIN · CNE100006KF0 HKEX Manufacturing
Open in API
Filings indexed 119 across all filing types
Latest filing 2026-05-15 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 2566

About Hangzhou Jiuyuan Gene Engineering Co., Ltd.

https://www.china-gene.com

Hangzhou Jiuyuan Gene Engineering Co., Ltd. is a biopharmaceutical enterprise founded in 1993, specializing in the research, development, manufacturing, and commercialization of gene engineering and biochemical products, including biopharmaceuticals and medical devices. The company centers its development efforts on four primary therapeutic areas: orthopedics, metabolic diseases, oncology, and hematology. Jiuyuan Gene is recognized as a pioneer in the domestic gene engineering sector. A significant milestone was the 1996 industrialization of recombinant human granulocyte colony-stimulating factor (rhG-CSF, Jilifen), which challenged the dominance of international competitors. Its product pipeline includes Jilifen, Jipailin, and the innovative implantable drug-device combination, Guyoudao. Guyoudao, which utilizes rhBMP-2 bone repair material, was the first product of its class to receive approval for sale in the domestic market.

Recent filings

Filing Released Lang Actions
RESTORATION OF PUBLIC FLOAT
Share Issue/Capital Change Classification · 85% confidence The document is a formal stock exchange announcement about the completion of the conversion of unlisted shares into H shares and the restoration of the company’s public float under the Listing Rules. This constitutes a change in the company’s share capital structure rather than an earnings, management, or regulatory report per se. It falls squarely under "Share Issue/Capital Change" announcements (“SHA”).
2026-05-15 English
Next Day Disclosure Returns
Share Issue/Capital Change Classification · 92% confidence The document is a regulatory listing return (Form FF305) under the Hong Kong Stock Exchange listing rules, disclosing changes in issued shares and treasury shares (conversion of domestic and foreign shares into H Shares and the resulting share counts). It is not the full financial report but an announcement of capital changes (share issuances/conversions). This falls squarely under Share Issue/Capital Change (SHA).
2026-05-14 English
INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION
Share Issue/Capital Change Classification · 88% confidence The document is an official announcement of the completion of the H share full circulation – namely the conversion of unlisted shares into H shares and the commencement of listing of the converted shares. This constitutes a change in the company’s capital structure (new share issue/conversion/listing) rather than management changes, dividends, or earnings. Hence it falls under Share Issue/Capital Change (SHA).
2026-05-14 English
CHANGE OF COMPANY NAME
Regulatory Filings Classification · 85% confidence The document is a stock exchange announcement notifying shareholders of the company’s change of registered company name. It does not provide financial results, management/board composition changes, share issuance, dividends, or an actual report. It is a general regulatory filing under Hong Kong Exchange requirements and falls into the fallback category for miscellaneous compliance announcements.
2026-05-11 English
INSIDE INFORMATION GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR IMPLEMENTATION OF THE H SHARE FULL CIRCULATION
Capital/Financing Update Classification · 95% confidence The document is an announcement from Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. regarding the grant of listing approval by the Stock Exchange for the implementation of the H Share full circulation. It details the conversion of unlisted shares into H shares and the approval of listing these shares. The document is an official announcement about a capital structure change, specifically the conversion and listing of shares. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. The content fits the category of a capital or financing update, as it relates to changes in the company's share capital and listing status. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-05-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filing (Form FF301) submitted to the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for the month ended 30 April 2026. It details movements in authorised/registered share capital, issued shares, treasury shares, and public float sufficiency confirmation. It is a regulatory compliance filing related to share capital and shareholding movements, not a financial report, earnings release, or management discussion. It does not contain financial statements or management commentary but is a regulatory disclosure required by the exchange. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-06 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.